Login to Your Account



Gilead’s HCV Drug Faces India Patent Challenge Over Pricing

By Mari Serebrov
Regulatory Editor

Wednesday, November 27, 2013

Although Gilead Sciences Inc.’s sofosbuvir could make history as the first interferon-free treatment to be approved for hepatitis C, it may face generic competition in India soon after it hits the market because it isn’t innovative enough, according to some advocacy groups.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription